Aravive, Inc. (41) | Uncategorized (19)

Recent Contracts

Offer Letter, dated June 2, 2022, by and between Aravive, Inc. and Rudy C. Howard (Filed With SEC on June 3, 2022)
Offer Letter between Leonard Scott Dove, Ph.D. and Aravive, Inc (Filed With SEC on March 22, 2022)
Offer Letter, dated September 8, 2020 between Reshma Rangwala and the Company (Filed With SEC on March 16, 2021)
Description of Capital Securities (Filed With SEC on March 16, 2021)
Amendment to Offer Letter dated as of January 25, 2021 by and between Aravive, Inc. and Gail McIntyre, Ph.D (Filed With SEC on January 27, 2021)
Option Agreement dated April 8, 2020 by and between the Company and Srini Akkaraju (Filed With SEC on April 9, 2020)
Amendment to Offer Letter dated as of April 8, 2020 by and between the Company and Gail McIntyre (Filed With SEC on April 9, 2020)
Option Agreement dated April 8, 2020 by and between the Company and Robert Hoffman (Filed With SEC on April 9, 2020)
Option Agreement dated April 8, 2020 by and between the Company and Jay Shepard (Filed With SEC on April 9, 2020)
Separation Agreement dated April 8, 2020 between the Company and Rekha Hemrajani (Filed With SEC on April 9, 2020)
Investment Agreement, dated as of April 6, 2020, by and among the Company, Eshelman Ventures, LLC, and, solely for purposes of Article IV and Article V of the Investment... (Filed With SEC on April 9, 2020)
Offer Letter, dated March 26, 2020 between Gail McIntyre and Aravive, Inc (Filed With SEC on March 27, 2020)
Offer Letter, dated March 26, 2020, between Vinay Shah and Aravive, Inc (Filed With SEC on March 27, 2020)
Description of Capital Securities (Filed With SEC on March 27, 2020)
Offer Letter, dated January 8, 2020, between Rekha Hemrajani and Aravive, Inc (Filed With SEC on January 9, 2020)
Amendment to Jay Shepard Offer Letter dated as of February 28, 2019 (Filed With SEC on March 6, 2019)
Offer Letter dated February 1, 2017 and the amendment thereto dated May 30, 2018 by and between Aravive Biologics, Inc. and Vinay Shah (Filed With SEC on February 12, 2019)
Offer Letter dated January 1, 2017 by and between Aravive Biologics, Inc. and Gail McIntyre (Filed With SEC on February 12, 2019)
Amendment to Jay Shepard Offer Letter dated as of February 6, 2019 (Filed With SEC on February 12, 2019)